- Home
- IOBT
IOBT
IO Biotech Inc.
as 12-18-2024 1:38pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 56.7M | IPO Year: | 2021 |
| Target Price: | $9.33 | AVG Volume (30 days): | 629.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $2.10 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest IO Biotech Inc. News
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
a month ago
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
a month ago
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Simply Wall St.
a month ago
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation
GlobeNewswire
2 months ago
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
GlobeNewswire
3 months ago
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Clinical Trials Arena
4 months ago
IO Biotech’s melanoma treatment trial to continue after IDMC review
MT Newswires
4 months ago
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
Compare IOBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.